Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Carboplatin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 243 Triple Negative Breast Neoplasms 125 Neoplasm Metastasis 23 Ovarian Neoplasms 18 Carcinoma, Non-Small-Cell Lung 14 Inflammatory Breast Neoplasms 13 Pancreatic Neoplasms 12 Neoplasms 10 Breast Neoplasms, Male 9 Colorectal Neoplasms 8 Stomach Neoplasms 7 Endometrial Neoplasms 7 Prostatic Neoplasms 6 Sarcoma 5 Pathologic Complete Response 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Fallopian Tube Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Carcinoma, Ductal, Breast 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Melanoma 4 Lung Neoplasms 4 HER2-positive Breast Cancer 4 Urinary Bladder Neoplasms 3 Recurrence 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 HER2-positive Early Breast Cancer 3

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡